Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase D2

CHEMBL4900 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:13:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4900
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase D2 as ChEMBL target CHEMBL4900, mapped to UniProt Q9BZL6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase D2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4900
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9BZL6
Serine/threonine-protein kinase D2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase D2 matters

As of 2026-09-13

Serine/threonine-protein kinase D2 is reviewed as Serine/threonine-protein kinase D2 (UniProt Q9BZL6); the current evidence base includes 15 approved drugs, 2157 compounds, and 357 assays, with lead potency reaching pChEMBL 9.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 2157 compounds, and 357 assays for this target. The dominant activity type is KI. CHEMBL1215000 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL1215000 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase D2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9BZL6, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2157
Total Compounds
357
Total Assays
15
Approved Drugs
IC50: 104.0, KI: 767.0, KD: 367.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1215000
 9.0 IC50 —
No preferred name
CHEMBL1215151
 9.0 IC50 —
No preferred name
CHEMBL388978
 8.9 IC50 —
No preferred name
CHEMBL5897911
 8.7 IC50 —
No preferred name
CHEMBL1214998
 8.7 IC50 —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
BRIGATINIB
CHEMBL3545311
 2017
NINTEDANIB
CHEMBL502835
 2014
DABRAFENIB
CHEMBL2028663
 2013
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:13:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4900